Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/17/2021 02/18/2021 02/19/2021 02/22/2021 02/23/2021 Date
256.82(c) 255.82(c) 247.93(c) 246.02(c) 247.7(c) Last
1 151 524 1 417 324 2 064 264 1 330 442 1 711 778 Volume
-0.20% -0.39% -3.08% -0.77% +0.68% Change
More quotes
Financials (USD)
Sales 2021 19 560 M - -
Net income 2021 2 331 M - -
Net Debt 2021 12 841 M - -
P/E ratio 2021 27,6x
Yield 2021 1,47%
Sales 2022 19 612 M - -
Net income 2022 2 579 M - -
Net Debt 2022 10 194 M - -
P/E ratio 2022 24,9x
Yield 2022 1,57%
Capitalization 71 972 M 71 972 M -
EV / Sales 2021 4,34x
EV / Sales 2022 4,19x
Nbr of Employees 72 000
Free-Float 79,2%
More Financials
Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (52.4%): surgical instruments (71.6% of net sales), pharmaceutical systems (16.2%), and diabetes care products (12.2%); - diagnostic materials (24.9%): automated systems for blood testing, mycobacteria... 
Sector
Medical Equipment, Supplies & Distribution
Calendar
02/24 | 01:00pmPresentation
More about the company
Notations Surperformance© of Becton, Dickinson and Company
Trading Rating : Investor Rating :
More Ratings
All news about BECTON, DICKINSON AND COMPANY
07:37aNABRIVA THERAPEUTICS : Study Demonstrates Macrolide-Resistance in S. pneumoniae ..
AQ
02/22BECTON DICKINSON AND : Dickinson to Collaborate With Scanwell Health to Create A..
MT
02/22BECTON DICKINSON AND : BD Announces Collaboration for At-Home Rapid Test for COV..
PR
02/18BECTON DICKINSON AND : FDA Circulatory System Devices Panel Voted Favorably on S..
PU
02/15BECTON DICKINSON AND : BD Announces Emergency Use Authorization, CE Mark for Com..
AQ
02/15BECTON DICKINSON AND : BD to Present at Upcoming Investor Conferences
AQ
02/12BECTON DICKINSON & CO : Entry into a Material Definitive Agreement, Creation of ..
AQ
02/12BECTON DICKINSON AND : BD to Present at Upcoming Investor Conferences
PR
02/12BECTON DICKINSON : FDA Grants EUA for New Test for SARS-CoV-2 and Influenza
DJ
02/12BECTON DICKINSON AND : Dickinson Receives FDA Emergency Use Authorization, CE Ma..
MT
02/12BECTON DICKINSON AND : BD Announces Emergency Use Authorization, CE Mark for Com..
PR
02/11BECTON DICKINSON & CO : Creation of a Direct Financial Obligation or an Obligati..
AQ
02/11BECTON DICKINSON AND : Q1 2021 Earnings Info Graphic
PU
02/10BECTON DICKINSON AND : Seeks to Raise About $1.7 Billion Through Debt Offerings
DJ
02/10BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-..
AQ
More news
News in other languages on BECTON, DICKINSON AND COMPANY
2020VIRUS : la fabrication de seringues tourne aussi à plein régime
2020Mettler Toledo prépare la transition à sa direction générale
2020OLIVIER FILLIOL : CEO Olivier Filliol wird durch Patrick Kaltenbach abgelöst
2020TESLA : Elon Musk a passé quatre tests Covid-19, dont deux positifs !
2020BECTON, DICKINSON AND COMPANY : Veröffentlichung des Jahresergebnisses
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 282,53 $
Last Close Price 247,70 $
Spread / Highest target 21,1%
Spread / Average Target 14,1%
Spread / Lowest Target 4,97%
EPS Revisions
Managers and Directors
NameTitle
Thomas E. Polen President, Chief Executive Officer & Director
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Vincent A. Forlenza Executive Chairman
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
BECTON, DICKINSON AND COMPANY-1.01%71 972
ABBOTT LABORATORIES11.93%214 001
MEDTRONIC PLC-1.19%159 002
HOYA CORPORATION-13.00%45 798
ALIGN TECHNOLOGY, INC.8.45%44 772
SARTORIUS STEDIM BIOTECH26.51%41 293